L Tosco1,2, A Laenen3, A Briganti4, P Gontero5, R J Karnes6, M Albersen1, P J Bastian7, P Chlosta8, F Claessens9, F K Chun10, W Everaerts1, C Gratzke7, M Graefen11, B Kneitz12, G Marchioro13, R S Salas14, B Tombal15, T Van den Broeck9, L Moris9, A Battaglia5, H van der Poel16, J Walz17, A Bossi18, G De Meerleer19, K Haustermans19, H Van Poppel1, M Spahn20, S Joniau1. 1. Department of Development and Regeneration, University Hospitals Leuven, Urology, Leuven, Belgium. 2. Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium. 3. Department of Public Health and Primary Care, Leuven Biostatistics and Statistical Bioinformatics Center, KU Leuven, Leuven, Belgium. 4. Department of Urology, San Raffaele Hospital, University VitaSalute, Milan, Italy. 5. Department of University Urology, Urologia U, Città della Salue e della Scienza di Torino, Molinette Hospital, Turin, Italy. 6. Department of Urology, Mayo Clinic, Rochester, MN, USA. 7. Department of Urology, Urologische Klinik Und Poliklinik, Klinikum Der Universität München Campus Großhadern, Munich, Germany. 8. Department of Urology, Jagiellonian University Medical College, Krakow, Poland. 9. Department of Cellular and Molecular Medicine, Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium. 10. Department of Urology, University of Hamburg, Hamburg, Germany. 11. Department of Urology, Martini Klinik am UKE GmbH, Hamburg, Germany. 12. Department of Urology and Pediatric Urology, University Hospital Wurzburg, Wurzburg, Germany. 13. Department of Urology, University of Piemonte Orientale, Novara, Italy. 14. Department of Urology, Institut Mutualiste Montsouris and Paris Descartes University, Paris, France. 15. Department of Urology, Cliniques Universitaires SaintLuc, Brussels, Belgium. 16. Department Of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 17. Department of Urology, Institut Paoli Calmettes Cancer Centre, Marseille, France. 18. Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France. 19. Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium. 20. Department of Urology, University Hospital Bern, Inselspital, Berne, Switzerland.
Abstract
BACKGROUND: Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there is a lack of knowledge regarding a possible effect of NHT on PCRD in the high-risk PCa population. We aimed to analyze the effect of NHT on PCRD in a multicenter high-risk PCa population treated with RP, using a propensity-score adjustment. METHODS: This is a retrospective multi-institutional study including patients with high-risk PCa defined as: clinical stage T3-4, PSA >20 ng ml-1 or biopsy Gleason score 8-10. We compared PCRD between RP and NHT+RP using competing risks analysis. Correction for group differences was performed by propensity-score adjustment. RESULTS: After application of the inclusion/exclusion criteria, 1573 patients remained for analysis; 1170 patients received RP and 403 NHT+RP. Median follow-up was 56 months (interquartile range 29-88). Eighty-six patients died of PCa and 106 of other causes. NHT decreased the risk of PCRD (hazard ratio (HR) 0.5; 95% confidence interval (CI) 0.32-0.80; P=0.0014). An interaction effect between NHT and radiotherapy (RT) was observed (HR 0.3; 95% CI 0.21-0.43; P<0.0008). More specifically, of patients who received adjuvant RT, those who underwent NHT+RP had decreased PCRD rates (2.3% at 5 year) compared to RP (7.5% at 5 year). The retrospective design and lack of specific information about NHT are possible limitations. CONCLUSIONS: In this propensity-score adjusted analysis from a large high-risk PCa population, NHT before surgery significantly decreased PCRD. This effect appeared to be mainly driven by the early addition of RT post-surgery. The specific sequence of NHT+RP and adjuvant RT merits further study in the high-risk PCa population.
BACKGROUND: Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there is a lack of knowledge regarding a possible effect of NHT on PCRD in the high-risk PCa population. We aimed to analyze the effect of NHT on PCRD in a multicenter high-risk PCa population treated with RP, using a propensity-score adjustment. METHODS: This is a retrospective multi-institutional study including patients with high-risk PCa defined as: clinical stage T3-4, PSA >20 ng ml-1 or biopsy Gleason score 8-10. We compared PCRD between RP and NHT+RP using competing risks analysis. Correction for group differences was performed by propensity-score adjustment. RESULTS: After application of the inclusion/exclusion criteria, 1573 patients remained for analysis; 1170 patients received RP and 403 NHT+RP. Median follow-up was 56 months (interquartile range 29-88). Eighty-six patients died of PCa and 106 of other causes. NHT decreased the risk of PCRD (hazard ratio (HR) 0.5; 95% confidence interval (CI) 0.32-0.80; P=0.0014). An interaction effect between NHT and radiotherapy (RT) was observed (HR 0.3; 95% CI 0.21-0.43; P<0.0008). More specifically, of patients who received adjuvant RT, those who underwent NHT+RP had decreased PCRD rates (2.3% at 5 year) compared to RP (7.5% at 5 year). The retrospective design and lack of specific information about NHT are possible limitations. CONCLUSIONS: In this propensity-score adjusted analysis from a large high-risk PCa population, NHT before surgery significantly decreased PCRD. This effect appeared to be mainly driven by the early addition of RT post-surgery. The specific sequence of NHT+RP and adjuvant RT merits further study in the high-risk PCa population.
Authors: William C Jackson; Matthew J Schipper; Skyler B Johnson; Corey Foster; Darren Li; Howard M Sandler; Ganesh S Palapattu; Daniel A Hamstra; Felix Y Feng Journal: Eur Urol Date: 2015-05-21 Impact factor: 20.096
Authors: Ryan K Berglund; Catherine M Tangen; Isaac J Powell; Bruce A Lowe; Gabriel P Haas; Peter R Carroll; Edith D Canby-Hagino; Ralph deVere White; George P Hemstreet; E David Crawford; Ian M Thompson; Eric A Klein Journal: Urology Date: 2012-03 Impact factor: 2.649
Authors: Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: James L Mohler; Philip W Kantoff; Andrew J Armstrong; Robert R Bahnson; Michael Cohen; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Timothy M Kuzel; Richard J Lee; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Edward Schaeffer; Eric J Small; Guru Sonpavde; Sandy Srinivas; Cy Stein; Seth A Strope; Jonathan Tward; Dorothy A Shead; Maria Ho Journal: J Natl Compr Canc Netw Date: 2014-05 Impact factor: 11.908
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: William R Polkinghorn; Joel S Parker; Man X Lee; Elizabeth M Kass; Daniel E Spratt; Phillip J Iaquinta; Vivek K Arora; Wei-Feng Yen; Ling Cai; Deyou Zheng; Brett S Carver; Yu Chen; Philip A Watson; Neel P Shah; Sho Fujisawa; Alexander G Goglia; Anuradha Gopalan; Haley Hieronymus; John Wongvipat; Peter T Scardino; Michael J Zelefsky; Maria Jasin; Jayanta Chaudhuri; Simon N Powell; Charles L Sawyers Journal: Cancer Discov Date: 2013-09-11 Impact factor: 39.397
Authors: Arie Carneiro; Marcelo Langer Wroclawski; Bruno Nahar; Andrey Soares; Ana Paula Cardoso; Nam Jin Kim; Fabricio Torres Carvalho Journal: Int Braz J Urol Date: 2020 Jul-Aug Impact factor: 1.541
Authors: Lorenzo Tosco; Annouschka Laenen; Thomas Gevaert; Isabelle Salmon; Christine Decaestecker; Elai Davicioni; Christine Buerki; Frank Claessens; Johan Swinnen; Karolien Goffin; Raymond Oyen; Wouter Everaerts; Lisa Moris; Gert De Meerleer; Karin Haustermans; Steven Joniau Journal: BMC Cancer Date: 2018-04-02 Impact factor: 4.430